Amedeo Smart

Free Medical Literature Service



Breast Cancer

  Free Subscription


1 Acta Cytol
4 Anticancer Res
2 BMC Cancer
3 Br J Cancer
1 Breast Cancer (Dove Med Press)
1 Breast Cancer Res
8 Breast Cancer Res Treat
1 Cancer Lett
3 Clin Breast Cancer
1 Curr Treat Options Oncol
2 Eur J Cancer
2 Eur J Surg Oncol
1 Eur Radiol
1 Gene
4 Int J Cancer
1 J Biol Chem
1 J Clin Oncol
1 J Pathol
1 NPJ Breast Cancer
3 Oncogene
5 PLoS One

    Acta Cytol

  1. NISHIMURA R, Murata Y, Mori K, Yamashiro K, et al
    Evaluation of the HER2 and Hormone Receptor Status in Metastatic Breast Cancer Using Cell Blocks: A Multi-Institutional Study.
    Acta Cytol. 2018 May 15:1-7. doi: 10.1159/000488382.
    >> Share

    Anticancer Res

  2. LIU LC, Wu YC, Kuo SC, Ho CT, et al
    2-Phenylnaphthyridin-4-one Derivative LYF-11 Inhibits Interleukin-6-mediated Epithelial-to-Mesenchymal Transition via the Inhibition of JAK2/STAT3 Signaling Pathway in MCF-7 Cells.
    Anticancer Res. 2018;38:2849-2859.
    >> Share

  3. OKARVI SM, Aljammaz I
    Preparation and In Vitro and In Vivo Characterization of the Tumor-specific Antigen-derived Peptide as a Potential Candidate for Targeting Human Epidermal Growth Factor Receptor 2-positive Breast Carcinomas.
    Anticancer Res. 2018;38:2823-2830.
    >> Share

  4. TATARA T, Mukohara T, Tanaka R, Shimono Y, et al
    3D Culture Represents Apoptosis Induced by Trastuzumab Better than 2D Monolayer Culture.
    Anticancer Res. 2018;38:2831-2839.
    >> Share

  5. LEHMANN-CHE J, Miquel C, Wong J, Callens C, et al
    First French Pilot Quality Assessment of the EndoPredict Test for Early Luminal Breast Carcinoma.
    Anticancer Res. 2018;38:2909-2914.
    >> Share

    BMC Cancer

  6. REYNOLDS KL, Bedard PL, Lee SH, Lin CC, et al
    A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.
    BMC Cancer. 2017;17:646.
    >> Share

  7. BATES JP, Derakhshandeh R, Jones L, Webb TJ, et al
    Mechanisms of immune evasion in breast cancer.
    BMC Cancer. 2018;18:556.
    >> Share

    Br J Cancer

    Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study'.
    Br J Cancer. 2018 May 17. pii: 10.1038/s41416-018-0060.
    >> Share

  9. GULLO G, Walsh N, Fennelly D, Bose R, et al
    Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the "one thousand HER2 patients" project.
    Br J Cancer. 2018 May 18. pii: 10.1038/s41416-018-0114.
    >> Share

  10. JOHNS LE, Jones ME, Schoemaker MJ, McFadden E, et al
    Reply to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study".
    Br J Cancer. 2018 May 17. pii: 10.1038/s41416-018-0092.
    >> Share

    Breast Cancer (Dove Med Press)

  11. FORSYTHE A, Chandiwana D, Barth J, Thabane M, et al
    Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancer.
    Breast Cancer (Dove Med Press). 2018;10:69-78.
    >> Share

    Breast Cancer Res

  12. ALLOUCHERY V, Beaussire L, Perdrix A, Sefrioui D, et al
    Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients.
    Breast Cancer Res. 2018;20:40.
    >> Share

    Breast Cancer Res Treat

  13. O'LOUGHLIN M, Andreu X, Bianchi S, Chemielik E, et al
    Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study.
    Breast Cancer Res Treat. 2018 May 17. pii: 10.1007/s10549-018-4825.
    >> Share

  14. BLOK EJ, Engels CC, Dekker-Ensink G, Meershoek-Klein Kranenbarg E, et al
    Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer.
    Breast Cancer Res Treat. 2018 May 15. pii: 10.1007/s10549-018-4785.
    >> Share

  15. ONO H, Sowa Y, Horinaka M, Iizumi Y, et al
    The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.
    Breast Cancer Res Treat. 2018 May 11. pii: 10.1007/s10549-018-4815.
    >> Share

  16. LU CY, Zhang F, Wagner AK, Nekhlyudov L, et al
    Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer.
    Breast Cancer Res Treat. 2018 May 12. pii: 10.1007/s10549-018-4821.
    >> Share

  17. LIN CH, Chuang PY, You SL, Chiang CJ, et al
    Effect of glucocorticoid use on survival in patients with stage I-III breast cancer.
    Breast Cancer Res Treat. 2018 May 14. pii: 10.1007/s10549-018-4787.
    >> Share

  18. KOTSOPOULOS J, Gronwald J, Lynch HT, Eisen A, et al
    Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res Treat. 2018 May 17. pii: 10.1007/s10549-018-4822.
    >> Share

  19. HOSTE G, Punie K, Wildiers H, Beuselinck B, et al
    Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer.
    Breast Cancer Res Treat. 2018 May 16. pii: 10.1007/s10549-018-4827.
    >> Share

  20. WILLIAMSON TJ, Love SM, Clague DeHart JN, Jorge-Miller A, et al
    Metastatic Breast Cancer Collateral Damage Project (MBCCD): Scale development and preliminary results of the Survey of Health, Impact, Needs, and Experiences (SHINE).
    Breast Cancer Res Treat. 2018 May 16. pii: 10.1007/s10549-018-4823.
    >> Share

    Cancer Lett

  21. YAN M, Wang Y, Wong CW, Mei-Yu Or P, et al
    PTEN PDZ-binding domain suppresses mammary carcinogenesis in the MMTV-PyMT breast cancer model.
    Cancer Lett. 2018 May 14. pii: S0304-3835(18)30337.
    >> Share

    Clin Breast Cancer

  22. KIM S, Moon BI, Lim W, Park S, et al
    Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers.
    Clin Breast Cancer. 2018 Mar 23. pii: S1526-8209(17)30736.
    >> Share

  23. QINGQING H, Jian Z, Dayong Z, Ziyi F, et al
    Robot-Assisted Internal Mammary Lymph Node Chain Dissection for Breast Cancer.
    Clin Breast Cancer. 2018 Apr 19. pii: S1526-8209(18)30134.
    >> Share

  24. CHO WK, Choi DH, Park W, Cha H, et al
    Effect of Body Mass Index on Survival in Breast Cancer Patients According to Subtype, Metabolic Syndrome, and Treatment.
    Clin Breast Cancer. 2018 Apr 19. pii: S1526-8209(17)30765.
    >> Share

    Curr Treat Options Oncol

  25. JASRA S, Anampa J
    Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review.
    Curr Treat Options Oncol. 2018;19:30.
    >> Share

    Eur J Cancer

  26. ZAHL PH
    Letter comments on EJC published paper: 'No overdiagnosis in the Norwegian Breast Cancer Screening Program estimated by combining record linkage and questionnaire information in the Norwegian Women and Cancer study'.
    Eur J Cancer. 2018 May 11. pii: S0959-8049(18)30774.
    >> Share

  27. LUND E, Nakamura A, Thalabard JC
    Re: No overdiagnosis in the Norwegian Breast Cancer Screening Program estimated by combining record linkage and questionnaire information in the Norwegian Women and Cancer Study.
    Eur J Cancer. 2018 May 11. pii: S0959-8049(18)30773.
    >> Share

    Eur J Surg Oncol

  28. TASOULIS MK, Iqbal FM, Cawthorn S, MacNeill F, et al
    Reply to: Subcutaneous implant breast reconstruction: The importance of objectively assessing the outcomes.
    Eur J Surg Oncol. 2018;44:273.
    >> Share

  29. ONESTI MG, Fanelli B, Di Taranto G
    Subcutaneous implant breast reconstruction: the importance of objectively assessing the outcomes.
    Eur J Surg Oncol. 2018;44:271-272.
    >> Share

    Eur Radiol

  30. CHEN BB, Lu YS, Yu CW, Lin CH, et al
    Imaging biomarkers from multiparametric magnetic resonance imaging are associated with survival outcomes in patients with brain metastases from breast cancer.
    Eur Radiol. 2018 May 16. pii: 10.1007/s00330-018-5448.
    >> Share


  31. BAGHI N, Bakhshinejad B, Keshavarz R, Babashah S, et al
    Dendrosomal nanocurcumin and exogenous p53 can act synergistically to elicit anticancer effects on breast cancer cells.
    Gene. 2018 May 10. pii: S0378-1119(18)30508-0. doi: 10.1016/j.gene.2018.
    >> Share

    Int J Cancer

  32. WU W, Chen F, Cui X, Yang L, et al
    LncRNA NKILA Suppresses TGF-beta-induced Epithelial-Mesenchymal Transition by Blocking NF-kappaB Signaling in Breast Cancer.
    Int J Cancer. 2018 May 15. doi: 10.1002/ijc.31605.
    >> Share

  33. LA MANNA S, Lee E, Ouzounova M, Di Natale C, et al
    Mimetics of Suppressor of cytokine signalling 3: novel potential therapeutics in triple breast cancer.
    Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31594.
    >> Share

  34. TROISI R, Gulbech Ording A, Grotmol T, Glimelius I, et al
    Pregnancy Complications and Subsequent Breast Cancer Risk in the Mother: A Nordic population-based case-control study.
    Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31600.
    >> Share

  35. LI J, Jing R, Wei H, Wang M, et al
    Germline mutations in 40 cancer susceptibility genes among Chinese patients with high hereditary risk breast cancer.
    Int J Cancer. 2018 May 12. doi: 10.1002/ijc.31601.
    >> Share

    J Biol Chem

  36. YAN T, Zhang A, Shi F, Chang F, et al
    Integrin alphavbeta3-associated DAAM1 is essential for collagen-induced invadopodia extension and cell haptotaxis in breast cancer cells.
    J Biol Chem. 2018 May 11. pii: RA117.000327. doi: 10.1074/jbc.RA117.000327.
    >> Share

    J Clin Oncol

  37. WANG L, Hong BY, Kennedy SA, Chang Y, et al
    Predictors of Unemployment After Breast Cancer Surgery: A Systematic Review and Meta-Analysis of Observational Studies.
    J Clin Oncol. 2018 May 14:JCO2017773663. doi: 10.1200/JCO.2017.77.3663.
    >> Share

    J Pathol

  38. DE GROOT JS, Ratze MAK, van Amersfoort M, Eisemann T, et al
    alphaE-catenin is a candidate tumor suppressor for the development of E-cadherin expressing lobular-type breast cancer.
    J Pathol. 2018 May 17. doi: 10.1002/path.5099.
    >> Share

    NPJ Breast Cancer

  39. STOVER DG, Gil Del Alcazar CR, Brock J, Guo H, et al
    Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer.
    NPJ Breast Cancer. 2018;4:10.
    >> Share


  40. TANG J, Li Y, Sang Y, Yu B, et al
    LncRNA PVT1 regulates triple-negative breast cancer through KLF5/beta-catenin signaling.
    Oncogene. 2018 May 15. pii: 10.1038/s41388-018-0310.
    >> Share

  41. WANG PS, Chou CH, Lin CH, Yao YC, et al
    A novel long non-coding RNA linc-ZNF469-3 promotes lung metastasis through miR-574-5p-ZEB1 axis in triple negative breast cancer.
    Oncogene. 2018 May 14. pii: 10.1038/s41388-018-0293.
    >> Share

  42. GALA K, Li Q, Sinha A, Razavi P, et al
    KMT2C mediates the estrogen dependence of breast cancer through regulation of ERalpha enhancer function.
    Oncogene. 2018 May 14. pii: 10.1038/s41388-018-0273.
    >> Share

    PLoS One

  43. FATIMA I, El-Ayachi I, Taotao L, Angeles Lillo M, et al
    Correction: The natural compound Jatrophone interferes with Wnt/beta-catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer.
    PLoS One. 2018;13:e0197796.
    >> Share

  44. ECKHARDT BL, Gagliardi M, Iles L, Evans K, et al
    Clinically relevant inflammatory breast cancer patient-derived xenograft-derived ex vivo model for evaluation of tumor-specific therapies.
    PLoS One. 2018;13:e0195932.
    >> Share

  45. LIM ST, Park CH, Kim SY, Nam SJ, et al
    The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer.
    PLoS One. 2018;13:e0197523.
    >> Share

  46. ZENG Z, Jiang X, Li X, Wells A, et al
    Conjugated equine estrogen and medroxyprogesterone acetate are associated with decreased risk of breast cancer relative to bioidentical hormone therapy and controls.
    PLoS One. 2018;13:e0197064.
    >> Share

  47. KHARMAN-BIZ A, Gao H, Ghiasvand R, Haldosen LA, et al
    Expression of the three components of linear ubiquitin assembly complex in breast cancer.
    PLoS One. 2018;13:e0197183.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016